EA201491541A1 - АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ - Google Patents

АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ

Info

Publication number
EA201491541A1
EA201491541A1 EA201491541A EA201491541A EA201491541A1 EA 201491541 A1 EA201491541 A1 EA 201491541A1 EA 201491541 A EA201491541 A EA 201491541A EA 201491541 A EA201491541 A EA 201491541A EA 201491541 A1 EA201491541 A1 EA 201491541A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
malignant
noroves
integrines
application
Prior art date
Application number
EA201491541A
Other languages
English (en)
Other versions
EA031069B1 (ru
Inventor
Морин РАЙАН
Джанго Сассман
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201491541A1 publication Critical patent/EA201491541A1/ru
Publication of EA031069B1 publication Critical patent/EA031069B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Изобретение относится к антителам, которые специфично связываются с интегрином αvβ6. Антитела могут быть полезными для лечения и диагностики различных видов злокачественных заболеваний, а также для детекции αvβ6.
EA201491541A 2012-02-17 2013-02-14 АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ EA031069B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US201261602511P 2012-02-23 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (2)

Publication Number Publication Date
EA201491541A1 true EA201491541A1 (ru) 2016-05-31
EA031069B1 EA031069B1 (ru) 2018-11-30

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491541A EA031069B1 (ru) 2012-02-17 2013-02-14 АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ

Country Status (14)

Country Link
US (5) US9493566B2 (ru)
EP (1) EP2814509B1 (ru)
JP (1) JP6273214B2 (ru)
KR (1) KR102084806B1 (ru)
CN (2) CN105017420B (ru)
AU (1) AU2013221585B2 (ru)
BR (1) BR112014019861A2 (ru)
CA (1) CA2862319C (ru)
EA (1) EA031069B1 (ru)
HK (1) HK1211035A1 (ru)
IL (1) IL233742B (ru)
MX (1) MX360141B (ru)
SG (1) SG11201404354UA (ru)
WO (1) WO2013123152A2 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2499395T3 (es) 2008-05-23 2014-09-29 Siwa Corporation Procedimientos para facilitar la regeneración
CN106232625B (zh) * 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
HUE051389T2 (hu) 2013-10-15 2021-03-01 Seagen Inc Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához
US10933112B2 (en) 2014-02-17 2021-03-02 Seagen Inc. Hydrophilic antibody-drug conjugates
US20170233452A1 (en) * 2014-04-23 2017-08-17 Immusoft Corporation Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
KR20230074837A (ko) 2016-02-19 2023-05-31 시와 코퍼레이션 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
CN109562152B (zh) 2016-08-09 2024-04-02 西雅图基因公司 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
MA46660A (fr) 2016-10-18 2019-08-28 Seattle Genetics Inc Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
KR102634762B1 (ko) 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
JP2020516648A (ja) * 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
CN110799217A (zh) 2017-04-27 2020-02-14 西雅图基因公司 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物
TN2020000059A1 (en) 2017-11-01 2022-01-06 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3755707A1 (en) 2018-02-20 2020-12-30 Seagen Inc. Hydrophobic auristatin f compounds and conjugates thereof
MX2022006132A (es) 2019-12-05 2022-06-17 Seagen Inc Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CA3176248A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
EP4326333A1 (en) 2021-04-20 2024-02-28 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
CN117580593A (zh) 2021-05-28 2024-02-20 思进公司 蒽环霉素抗体结合物
US20230381321A1 (en) 2022-03-17 2023-11-30 Seagan Inc., Camptothecin conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
AU739283B2 (en) 1997-08-08 2001-10-11 Regents Of The University Of California, The Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6
DE60230736D1 (de) * 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
IL164021A0 (en) * 2002-03-13 2005-12-18 Univ California Antibodies and anti-pharmaceutical compositions containing the same
UA90242C2 (ru) * 2002-03-13 2010-04-26 Байоджен Айдек Ма Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6
EP1492870A4 (en) 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
CA2582157A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
EA013323B1 (ru) * 2004-12-09 2010-04-30 Сентокор, Инк. Иммуноконъюгаты против интегрина, способы и варианты применения
US7592426B2 (en) 2005-03-10 2009-09-22 Morphotek, Inc. Anti-mesothelin antibodies
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
JP2009505673A (ja) 2005-08-31 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子特異抗体及びその使用
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
JP2010506944A (ja) 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
JP2011509687A (ja) * 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
CN101959929B (zh) 2008-03-27 2013-05-01 泰尔茂株式会社 生物体吸收性材料及使用其的生物体内留置物
WO2009135953A2 (en) 2008-05-09 2009-11-12 Ablynx Nv Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
KR101138460B1 (ko) * 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
US20150086570A1 (en) 2012-03-29 2015-03-26 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
MX360141B (es) 2018-10-24
BR112014019861A2 (pt) 2017-07-04
KR102084806B1 (ko) 2020-03-04
US20160376368A1 (en) 2016-12-29
US20200031938A1 (en) 2020-01-30
CN105017420B (zh) 2019-05-28
US9493566B2 (en) 2016-11-15
CN105017420A (zh) 2015-11-04
IL233742B (en) 2019-08-29
KR20140127875A (ko) 2014-11-04
US20210340260A1 (en) 2021-11-04
US20160009806A1 (en) 2016-01-14
EP2814509A2 (en) 2014-12-24
WO2013123152A3 (en) 2014-11-13
AU2013221585A1 (en) 2014-08-14
AU2013221585B2 (en) 2017-03-30
MX2014009751A (es) 2015-02-24
EP2814509A4 (en) 2015-12-09
EP2814509B1 (en) 2018-05-16
EA031069B1 (ru) 2018-11-30
CN104220094A (zh) 2014-12-17
IL233742A0 (en) 2014-09-30
US20230242648A1 (en) 2023-08-03
JP2015509938A (ja) 2015-04-02
SG11201404354UA (en) 2014-10-30
WO2013123152A2 (en) 2013-08-22
CA2862319A1 (en) 2013-08-22
CA2862319C (en) 2021-11-30
HK1211035A1 (en) 2016-05-13
JP6273214B2 (ja) 2018-01-31

Similar Documents

Publication Publication Date Title
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
MA34091B1 (fr) Anticorps anti-cd40
EA201790413A1 (ru) Антитела против tigit
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA202193044A2 (ru) Способы лечения таупатии
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201400579A1 (ru) Антитела к il-36r
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent